Targeting hypertensive myocardial fibrosis

Michele M. Ciulla, Roberta Paliotti, Cesare Cuspidi

Research output: Contribution to journalArticle

Abstract

In normal myocardium, myocytes represent only one-third of all cells, with the remaining two-thirds including fibroblasts and small cellular populations. While several weeks post partum the myocyte count stops increasing, the connective tissue cell count does not. In the early phases of arterial hypertension, adaptive left ventricular (LV) hypertrophy (LVH) is characterised by the growth of cardiac myocytes, which may or may not be accompanied by other alterations in tissue structure. In hypertensive heart disease, however, complex changes in myocardial composition occur, with a disproportionate involvement of noncardiomyocyte cells accounting for a pathological remodelling of tissue structure (pathological hypertrophy). Myocardial fibrosis is the result of both haemodynamic and nonhaemodynamic factors playing a synergistic role and reflects the loss of the physiological reciprocal regulation between stimulatory and inhibitory factors acting on the turnover of fibrillar collagen. Cardiac biopsy is the gold standard for assessing myocardial fibrosis; in the last decades different non-invasive approaches have been developed and validated to detect and follow-up cardiac fibrosis, including biochemical markers of collagen synthesis and degradation, cardiac hormones and ultrasonographic procedures. Due to the clinical implications of myocardial fibrosis and pathological LVH, it is of great interest to ascertain the effect of antihypertensive agents on cardiac structure: the optimal treatment of hypertensive patients should target a parallel decrease in cardiac mass and fibrosis. Preliminary evidence suggests that not all antihypertensive drugs affect fibrosis to the same extent: angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers (ARBs) appear particularly effective, in contrast to β-blockers and diuretics. Finally, the impact of fibrosis and its regression on subsequent cardiovascular events when compared with LV mass and its reduction remain to be investigated.

Original languageEnglish
Pages (from-to)225-230
Number of pages6
JournalHigh Blood Pressure and Cardiovascular Prevention
Volume12
Issue number4
DOIs
Publication statusPublished - 2005

Fingerprint

Fibrosis
Muscle Cells
Hypertrophy
Antihypertensive Agents
Fibrillar Collagens
Connective Tissue Cells
Angiotensin Receptor Antagonists
Left Ventricular Hypertrophy
Angiotensin-Converting Enzyme Inhibitors
Diuretics
Cardiac Myocytes
Heart Diseases
Myocardium
Collagen
Fibroblasts
Cell Count
Biomarkers
Hemodynamics
Hormones
Hypertension

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Targeting hypertensive myocardial fibrosis. / Ciulla, Michele M.; Paliotti, Roberta; Cuspidi, Cesare.

In: High Blood Pressure and Cardiovascular Prevention, Vol. 12, No. 4, 2005, p. 225-230.

Research output: Contribution to journalArticle

Ciulla, Michele M. ; Paliotti, Roberta ; Cuspidi, Cesare. / Targeting hypertensive myocardial fibrosis. In: High Blood Pressure and Cardiovascular Prevention. 2005 ; Vol. 12, No. 4. pp. 225-230.
@article{308089973df74ed2a2d0b6255e56ffec,
title = "Targeting hypertensive myocardial fibrosis",
abstract = "In normal myocardium, myocytes represent only one-third of all cells, with the remaining two-thirds including fibroblasts and small cellular populations. While several weeks post partum the myocyte count stops increasing, the connective tissue cell count does not. In the early phases of arterial hypertension, adaptive left ventricular (LV) hypertrophy (LVH) is characterised by the growth of cardiac myocytes, which may or may not be accompanied by other alterations in tissue structure. In hypertensive heart disease, however, complex changes in myocardial composition occur, with a disproportionate involvement of noncardiomyocyte cells accounting for a pathological remodelling of tissue structure (pathological hypertrophy). Myocardial fibrosis is the result of both haemodynamic and nonhaemodynamic factors playing a synergistic role and reflects the loss of the physiological reciprocal regulation between stimulatory and inhibitory factors acting on the turnover of fibrillar collagen. Cardiac biopsy is the gold standard for assessing myocardial fibrosis; in the last decades different non-invasive approaches have been developed and validated to detect and follow-up cardiac fibrosis, including biochemical markers of collagen synthesis and degradation, cardiac hormones and ultrasonographic procedures. Due to the clinical implications of myocardial fibrosis and pathological LVH, it is of great interest to ascertain the effect of antihypertensive agents on cardiac structure: the optimal treatment of hypertensive patients should target a parallel decrease in cardiac mass and fibrosis. Preliminary evidence suggests that not all antihypertensive drugs affect fibrosis to the same extent: angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers (ARBs) appear particularly effective, in contrast to β-blockers and diuretics. Finally, the impact of fibrosis and its regression on subsequent cardiovascular events when compared with LV mass and its reduction remain to be investigated.",
author = "Ciulla, {Michele M.} and Roberta Paliotti and Cesare Cuspidi",
year = "2005",
doi = "10.2165/00151642-200512040-00004",
language = "English",
volume = "12",
pages = "225--230",
journal = "High Blood Pressure and Cardiovascular Prevention",
issn = "1120-9879",
publisher = "Adis International Ltd",
number = "4",

}

TY - JOUR

T1 - Targeting hypertensive myocardial fibrosis

AU - Ciulla, Michele M.

AU - Paliotti, Roberta

AU - Cuspidi, Cesare

PY - 2005

Y1 - 2005

N2 - In normal myocardium, myocytes represent only one-third of all cells, with the remaining two-thirds including fibroblasts and small cellular populations. While several weeks post partum the myocyte count stops increasing, the connective tissue cell count does not. In the early phases of arterial hypertension, adaptive left ventricular (LV) hypertrophy (LVH) is characterised by the growth of cardiac myocytes, which may or may not be accompanied by other alterations in tissue structure. In hypertensive heart disease, however, complex changes in myocardial composition occur, with a disproportionate involvement of noncardiomyocyte cells accounting for a pathological remodelling of tissue structure (pathological hypertrophy). Myocardial fibrosis is the result of both haemodynamic and nonhaemodynamic factors playing a synergistic role and reflects the loss of the physiological reciprocal regulation between stimulatory and inhibitory factors acting on the turnover of fibrillar collagen. Cardiac biopsy is the gold standard for assessing myocardial fibrosis; in the last decades different non-invasive approaches have been developed and validated to detect and follow-up cardiac fibrosis, including biochemical markers of collagen synthesis and degradation, cardiac hormones and ultrasonographic procedures. Due to the clinical implications of myocardial fibrosis and pathological LVH, it is of great interest to ascertain the effect of antihypertensive agents on cardiac structure: the optimal treatment of hypertensive patients should target a parallel decrease in cardiac mass and fibrosis. Preliminary evidence suggests that not all antihypertensive drugs affect fibrosis to the same extent: angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers (ARBs) appear particularly effective, in contrast to β-blockers and diuretics. Finally, the impact of fibrosis and its regression on subsequent cardiovascular events when compared with LV mass and its reduction remain to be investigated.

AB - In normal myocardium, myocytes represent only one-third of all cells, with the remaining two-thirds including fibroblasts and small cellular populations. While several weeks post partum the myocyte count stops increasing, the connective tissue cell count does not. In the early phases of arterial hypertension, adaptive left ventricular (LV) hypertrophy (LVH) is characterised by the growth of cardiac myocytes, which may or may not be accompanied by other alterations in tissue structure. In hypertensive heart disease, however, complex changes in myocardial composition occur, with a disproportionate involvement of noncardiomyocyte cells accounting for a pathological remodelling of tissue structure (pathological hypertrophy). Myocardial fibrosis is the result of both haemodynamic and nonhaemodynamic factors playing a synergistic role and reflects the loss of the physiological reciprocal regulation between stimulatory and inhibitory factors acting on the turnover of fibrillar collagen. Cardiac biopsy is the gold standard for assessing myocardial fibrosis; in the last decades different non-invasive approaches have been developed and validated to detect and follow-up cardiac fibrosis, including biochemical markers of collagen synthesis and degradation, cardiac hormones and ultrasonographic procedures. Due to the clinical implications of myocardial fibrosis and pathological LVH, it is of great interest to ascertain the effect of antihypertensive agents on cardiac structure: the optimal treatment of hypertensive patients should target a parallel decrease in cardiac mass and fibrosis. Preliminary evidence suggests that not all antihypertensive drugs affect fibrosis to the same extent: angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers (ARBs) appear particularly effective, in contrast to β-blockers and diuretics. Finally, the impact of fibrosis and its regression on subsequent cardiovascular events when compared with LV mass and its reduction remain to be investigated.

UR - http://www.scopus.com/inward/record.url?scp=33644683439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644683439&partnerID=8YFLogxK

U2 - 10.2165/00151642-200512040-00004

DO - 10.2165/00151642-200512040-00004

M3 - Article

AN - SCOPUS:33644683439

VL - 12

SP - 225

EP - 230

JO - High Blood Pressure and Cardiovascular Prevention

JF - High Blood Pressure and Cardiovascular Prevention

SN - 1120-9879

IS - 4

ER -